NCT06561360 2026-03-18
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Genmab
M.D. Anderson Cancer Center